Company intelligence / Profile preview
Solaxa
Bethesda, Maryland, United Statessolaxa.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Solaxa is a clinical-stage biopharmaceutical company developing aminopyridine-based small molecule therapies to restore nerve function in rare neurodegenerative diseases and acute nerve injuries. Its lead candidate, SLX‑100, is entering a pivotal Phase 3 trial for spinocerebellar ataxia type 27B. The company has demonstrated treatment response in multiple forms of ataxia and has studied over 250 patients with its drug candidates.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeAminopyridine drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
National Ataxia Foundation (collaborative research and genetic testing initiatives)
Beyond the preview
Go deeper on Solaxa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solaxa.